Dexcom has received a warning letter from the FDA, after the agency uncovered issues during two inspections of the continuous ...

Medical device companies presented new data this week at the Advanced Technologies & Treatments for Diabetes conference.

Operating income (non-GAAP) decreased to $209.5 million from $242.7 million. DexCom reported mixed earnings, with revenue surpassing estimates but earnings per share falling short. DexCom ...

17:02 EST DexCom (DXCM) falls 7% to $71.99 after receiving warning letter from FDA See what stocks are receiving Strong Buy ratings from top-rated analysts. Filter, analyze, and streamline your ...

The FDA cited issues with DexCom's response to prior inspection findings, known as Form 483 observations. The inspections took place at the San Diego facility between October 21 and November 7 ...

Shares of DexCom Inc. DXCM rallied 3.79% to $73.38 Wednesday, on what proved to be an all-around positive trading session for ...

The announcement came after a quarter where DexCom reported a 7% increase in sales, though net income declined significantly alongside a reduction in earnings per share. During the past quarter ...

DexCom, Inc. (NASDAQ ... the Middle East and North Africa—90-95%6,7 of whom have Type 2 diabetes. “With policymakers increasingly focused on digital transformation in healthcare, now is ...